Investors / United States / Ascenta Capital
Ascenta Capital
Venture capital · New York, NY, United States · North America
Ascenta Capital is a biotech venture capital firm that makes concentrated investments in innovative companies and works collaboratively with management teams. It supports companies with strategic and operational experience as they advance clinical development of medicines.
Invests inHealthcare & Biotech
In its own wordsbiotechdrug developmentclinical developmenttherapeuticsplatformslife sciences
Your fit with Ascenta Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAscenta Capital lists 11 checked portfolio companies on its own site and is named in 5 funding rounds, 3 of them as lead. Its most frequent entry is Growth, 60% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 90% of its companies are based in United States. It invests most often alongside Lightspeed Venture Partners, RA Capital and Atlas Venture.
Counts come from funding rounds that name Ascenta Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Ascenta Capital's whole history. Rounds on record name 5 companies; its own site lists 11. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundAscenta Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 40% |
| Growth | 60% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 3 | 2 |
| '26 | 1 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 99th | 45% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Lightspeed Venture Partners | 3 |
| RA Capital | 3 |
| Atlas Venture | 2 |
| Catalio Capital Management | 2 |
| Delos Capital | 2 |
| Foresite Capital | 2 |
| Frazier Life Sciences | 2 |
| Longitude Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Lightspeed Venture Partners
Compare Ascenta Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Ascenta Capital| Date | Company | Stage |
|---|---|---|
| 17 Jun 2026 | Series C+ Led | |
| 3 Dec 2025 | Series B Led | |
| 10 Nov 2025 | Series B Led | |
| 15 Oct 2025 | Series C+ | |
| 23 Oct 2024 | Series C+ |
Round details for Ascenta Capital
Amounts, full round histories and every co-investor in Ascenta Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alpha-9 Oncology is a clinical stage radiopharmaceutical company advancing a portfolio of molecules to treat cancer cells | Healthcare & Biotech | Oct 2024Series C+ | Page + round | |
| Adarx Pharmaceuticals is developing next-generation siRNA therapeutics to treat various diseases. | Healthcare & Biotech | Portfolio page | ||
| Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | Healthcare & Biotech | Portfolio page | ||
| Cardurion translates its expertise in cardiovascular signaling pathways into groundbreaking therapeutics for patients with cardiovascular disease. | Healthcare & Biotech | Portfolio page | ||
| Iambic Therapeutics develops medicines using artificial intelligence and molecular technologies | Healthcare & Biotech | Nov 2025Series B | Page + round | |
| Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines | Healthcare & Biotech | Portfolio page | ||
| Odyssey Therapeutics develops therapeutic candidates for autoimmune and inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, MASH, and more. | Healthcare & Biotech | Portfolio page | ||
| Triana Biomedicines discovers and develops small molecules that induce proximity of proteins to inactivate drivers of disease and deliver transformative therapies to patients | Healthcare & Biotech | Dec 2025Series B | Page + round | |
| Triveni Bio is a clinical-stage biotech company taking a genetics-informed approach and leveraging advanced antibody engineering to build first-in-class therapeutics for immune and inflammatory diseases. | Healthcare & Biotech | Jun 2026Series C+ | Page + round | |
| Tubulis generates uniquely matched antibody-drug conjugates for cancer treatment | Healthcare & Biotech | Oct 2025Series C+ | Page + round |
About this data
site last read 5 Nov 2026- Site
- ascentacap.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 23 Oct 2024
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Ascenta Capital's profile as data
Pull Ascenta Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/ascentacap.com
# also
GET /v1/firms/ascentacap.com/portfolio
GET /v1/firms/ascentacap.com/coinvestors
GET /v1/firms/ascentacap.com/news